Used in targeted cancer therapy, particularly in the treatment of hepatocellular carcinoma and colorectal cancer. Acts as a selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and fibroblast growth factor receptor-1 (FGFR-1), blocking signaling pathways involved in tumor angiogenesis and tumor cell proliferation. By inhibiting these receptors, it helps suppress the formation of new blood vessels that feed tumors and directly hinders cancer cell growth. Has been evaluated in clinical trials both as a monotherapy and in combination with other anticancer agents to improve efficacy in advanced solid tumors. Its dual inhibition mechanism offers potential benefit in tumors resistant to single-pathway inhibitors.